Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies

Clinics in Dermatology

Volumn 28, Issue 1, 2010, Pages 88-92

  Naldi, Luigi ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; FOLIC ACID; INFLIXIMAB; METHOTREXATE; PLACEBO; PSORALEN;

ARTICLE; BASAL CELL CARCINOMA; BODY MASS; CANCER RISK; CLINICAL TRIAL; COMORBIDITY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; KAPOSI SARCOMA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; OBESITY; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUVA; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SKIN CANCER; SMOKING; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

BIOLOGICAL PRODUCTS; COLONIC NEOPLASMS; CYCLOSPORINE; DERMATOLOGIC AGENTS; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; LYMPHOMA; METHOTREXATE; MYCOPHENOLIC ACID; NEOPLASMS; PHOTOTHERAPY; PSORIASIS; PUVA THERAPY; SKIN NEOPLASMS; ULTRAVIOLET THERAPY;

EID: 71749099998     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2009.03.003     Document Type: Article

References (47)

1. Hannay P.W. Squamous cell epithelioma and psoriasis. Arch Dermatol Syphilol 60 (1949) 430-434
2. Conn H.O., Snyder N., and Atterbury C.E. The Berkson bias in action. Yale J Biol Med 52 (1979) 141-147
3. Naldi L., Chatenoud L., Linder D., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125 (2005) 61-67
4. Vessey M.P., Painter R., and Powell J. Skin disorders in relation to oral contraception and other factors, includingage, social class, smoking and body mass index. Findings in a large cohort study. Br J Dermatol 143 (2000) 815-820
5. Setty A.R., Curhan G., and Choi H.K. Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med 120 (2007) 953-959
6. Huerta C., Rivero E., and Rodríguez L.A. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 143 (2007) 1559-1565
7. Setty A.R., Curhan G., and Choi H.K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 167 (2007) 1670-1675
8. Boffetta P., Gridley G., and Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 117 (2001) 1531-1537
9. Olsen J.H., Møller H., and Frentz G. Malignant tumors in patients with psoriasis. J Am Acad Dermatol 27 (1992) 716-722
10. Calle E.E., Rodriguez C., Walker-Thurmond K., and Thun J.M. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348 (2003) 1625-1638
11. Samanic C., Gridley G., Chow W.H., Lubin J., Hoover R.N., and Fraumeni Jr. J.F. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 15 (2004) 35-43
12. Stern R.S., and Lange R. members of the Photochemotherapy Follow-up Study. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol 91 (1988) 197-201
13. Gelfand J.M., Berlin J., Van Voorhees A., and Margolis D.J. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 139 (2003) 1425-1429
14. Le Moual N., Kauffmann F., Eisen E.A., and Kennedy S.M. The healthy worker effect in asthma: work may cause asthma, but asthma may also influence work. Am J Respir Crit Care Med 177 (2008) 4-10
15. Lecluse L.L., Naldi L., Stern R.S., and Spuls P.I. National Registries of Systemic Treatment for Psoriasis and the European 'Psonet Initiative. Dermatology 218 (2009) 347-356
16. Chen J., Ruczinski I., Jorgensen T.J., et al. Nonmelanoma skin cancer and risk for subsequent malignancy. J Natl Cancer Inst 100 (2008) 1215-1222
17. Stern R.S., Laird N., Melski J., Parrish J.A., Fitzpatrick T.B., and Bleich H.L. Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 310 (1984) 1156-1161
18. Stern R.S., and Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 91 (1988) 120-124
19. Nijsten T.E.C., and Stern R.S. The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study. J Invest Dermatol 121 (2003) 252-258
20. Stern R.S., Nichols K.T., and Väkevä L.H. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 336 (1997) 1041-1045
21. Stern R.S., and Lunder E.J. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 134 (1998) 1582-1585
22. Hannuksela-Svahn A., Sigurgeirsson B., Pukkala E., et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 141 (1999) 497-501
23. Morison W.L., Baughman R.D., Day R.M., et al. Consensus workshop on the toxic effects of long term PUVA therapy. Arch Dermatol 134 (1998) 595-598
24. Pieternel C.M., Pasker-de-Jong M., Wielink G., et al. Treatment with UV-B for psoriasis and nonmelanoma skin cancer. A systematic review of the literature. Arch Dermatol 135 (1999) 834-840
25. Lee E., Koo J., and Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol 44 (2005) 355-360
26. Hearn R.M., Kerr A.C., Rahim K.F., Ferguson J., and Dawe R.S. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 159 (2008) 931-935
27. Ibbotson S.H., Bilsland D., Cox N.H., et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol 151 (2004) 283-297
28. Prey S., and Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 160 (2009) 622-628
29. Stern R.S., and Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy follow-up study. Cancer 73 (1994) 2759-2764
30. Nyfors A., and Jensen H. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study. Dermatologica 167 (1983) 260-261
31. Stern R.S. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol 142 (2006) 1132-1135
32. Salliot C., and van der Heijde D. Long term safety of Methotrexate monotherapy in rheumatoid arthritis patients: A systematic literature research. Annals of the Rheumatic Diseases 68 (2009) 1100-1104
33. Naldi L., and Griffiths C.E. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 152 (2005) 597-615
34. Zafar S.Y., Howell D.N., and Gockerman J.P. Malignancy after solid organ transplantation: an overview. Oncologist 13 (2008) 769-778
35. Naldi L., Fortina A.B., Lovati S., et al. Risk of nonmelanoma skin cancer in Italian organ transplant recipients. A registry-based study. Transplantation 70 (2000) 1479-1484
36. Molmenti E.P., Nagata D.E., Roden J.S., et al. Post-transplant lymphoproliferative syndrome in the pediatric liver transplant population. Am J Transplant 1 (2001) 356-359
37. Bates W.D., Gray D.W.R., Dada M.A., et al. Lymphoproliferative disorders in Oxford renal transplant recipients. J Clin Pathol 56 (2003) 439-446
38. Mercil I., and Stern R.S. Squamous cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 358 (2001) 1042-1045
39. Paul C.F., Ho V.C., McGeown C., et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 120 (2003) 211-216
40. Descotes J., and Gouraud A. Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol 4 (2008) 1537-1549
41. Goffe B., Papp K., Gratton D., et al. An integrated analysis of thirteen trials summarising the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 27 (2005) 1912-1921
42. Brimhall A.K., King L.N., Licciardone J.C., Jacobe H., and Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 159 (2008) 274-285
43. Papp K.A., Bressinck R., Fretzin S., et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb randomized controlled trial. Int J Dermatol 45 (2006) 605-614
44. Vincenti F., and Mendez R. Pescovitz M,et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 7 (2007) 1770-1777
45. Tyring S., Gordon K.B., Poulin Y., et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 143 (2007) 719-726
46. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
47. Naldi L. A new era in the management of psoriasis? Promises and facts. Dermatology 210 (2005) 179-181